Cite
MLA Citation
N/A. “Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.” Pancreas, vol. 46, no. 7, 2017, p. . http://access.bl.uk/ark:/81055/vdc_100049360141.0x000020